Atai Life Sciences N.V. (ATAI)’s BPL-003 Achieves Robust Phase 2b Success in Treatment-Resistant Depression

We recently compiled a list of the 13 Best Psychedelic Stocks to Invest in Now. Atai Life Sciences N.V. is one of them.

Atai Life Sciences N.V. (NASDAQ:ATAI), a clinical-stage biopharmaceutical company, is developing innovative psychedelic-based treatments for mental health disorders, including treatment-resistant depression (TRD). The company focuses on therapies with short in-clinic treatment durations that provide rapid and durable antidepressant effects.

Recent developments highlight a strategic merger with Beckley Psytech, aimed at consolidating expertise and late-stage assets to accelerate the delivery of impactful mental health therapies. This move is expected to strengthen the corporation’s position as a global leader in psychedelic therapeutics, making Atai Life Sciences N.V. (NASDAQ:ATAI) one of the best psychedelic stocks for investors focused on innovative treatments.

In clinical progress, BPL-003 (intranasal mebufotenin benzoate) showed positive topline results from the blinded stage of its Phase 2b trial in TRD patients. The therapy met primary and secondary endpoints, demonstrating rapid, robust, and durable antidepressant effects lasting up to eight weeks after a single dose. Results from the open-label extension are anticipated in Q3 2025. Atai Life Sciences N.V. (NASDAQ:ATAI) plans to file an End-of-Phase 2 meeting request with the FDA in Q3 2025 to advance BPL-003’s clinical development pathway.

Atai Life Sciences N.V. (ATAI)’s BPL-003 Achieves Robust Phase 2b Success in Treatment-Resistant Depression

Financially, Atai Life Sciences N.V. (NASDAQ:ATAI) has raised nearly $140 million in 2025, reflecting strong investor confidence in its strategy and pipeline. Positive clinical data and strategic initiatives drove significant stock momentum in August 2025, underscoring market optimism.

While we acknowledge the risk and potential of ATAI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ATAI and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure. None.